Integrated Management of Erectile Dysfunction
Management of ED should extend beyond prescribing medication for erectile function. Treatment selection should consider the underlying etiology, overall health, cardiovascular risk, hormonal status, psychological factors, and patient expectations.
Current EAU guidance recommends lifestyle and risk-factor modification before or alongside ED treatment, with PDE5 inhibitors recommended as first-line pharmacological therapy in appropriate patients.
Step One: Address Modifiable Risk Factors
Before focusing exclusively on erectile performance, clinicians should assess factors affecting vascular and metabolic health.
Management may include:
- Optimizing glycemic control.
- Managing hypertension.
- Treating dyslipidemia.
- Weight reduction when appropriate.
- Increasing physical activity.
- Smoking cessation.
- Addressing unhealthy lifestyle factors.
Lifestyle modification and risk-factor management are recommended before or alongside ED-specific treatment.
Pharmacological Treatment
PDE5 inhibitors are recommended as first-line pharmacological therapy for most appropriate patients.
Common agents include:
- Sildenafil.
- Tadalafil.
- Vardenafil.
- Avanafil.
Drug selection and dosing should be individualized according to comorbidities, concomitant medications, contraindications, and patient preference.
A particularly important safety consideration is the use of nitrates, as combining nitrates with PDE5 inhibitors can result in potentially dangerous hypotension.
Non-Oral Treatment Options
When oral therapy is ineffective, contraindicated, or not preferred, other approaches may be considered.
These include:
- Intracavernosal injections.
- Intraurethral or topical alprostadil in selected patients.
- Vacuum erection devices.
These options should be selected according to efficacy, safety, invasiveness, tolerability, and patient preference
Surgical Treatment
For selected patients with persistent ED who do not respond to or do not wish to use other treatment options, penile prosthesis implantation may provide an effective definitive treatment.
Clinical decision-making should include discussion of:
- Expected efficacy.
- Surgical risks.
- Potential complications.
- Available device options.
- Patient expectations.
Psychological and Psychosexual Management
Psychological factors should not be overlooked, even when an organic cause has been identified.
Performance anxiety, depression, relationship difficulties, and other psychosocial factors may contribute to ED or amplify its severity.
Psychological or psychosexual counseling can therefore be incorporated into the management plan when clinically indicated.
What About Regenerative Therapies?
Regenerative approaches have attracted increasing research interest in ED, including:
- Platelet-Rich Plasma (PRP).
- Stem cell-based therapies.
- Other cellular and molecular approaches.
However, clinicians should clearly distinguish early clinical research from established standard-of-care treatment.
Promising preliminary findings do not automatically establish a therapy as clinically proven. Emerging interventions should therefore be evaluated according to the quality of evidence, regulatory requirements, ethical standards, and appropriate patient selection.
They should not be presented as guaranteed treatments.
Regen's Multidisciplinary Model
Selected patients may benefit from multidisciplinary collaboration involving:
- Urology.
- Andrology.
- Endocrinology.
- Cardiology.
- Psychology / Psychosexual Medicine.
- Regenerative Medicine.
This approach allows ED to be addressed as part of the patient’s broader health profile rather than as an isolated sexual symptom.
Treatment Follow-Up
Treatment success depends not only on initiating therapy but also on structured follow-up.
Clinicians may reassess:
- Erectile function.
- Patient satisfaction.
- Treatment adherence.
- Adverse effects.
- Cardiometabolic risk factors.
- Overall health status.
Validated instruments such as IIEF and SHIM can support structured assessment of treatment response over